Core Viewpoint - The company is advancing its globalization strategy by establishing a research and development office in Boston, covering approximately 2,000 square meters, which has already begun generating revenue [2] Group 1: Global Expansion Strategy - The company aims to increase the proportion of overseas customer revenue to about 47% by 2025, with a positive year-on-year growth in new overseas orders [2] - The Boston laboratory will collaborate with domestic research centers to share resources and achieve differentiated development, focusing on meeting the growing demands of overseas clients [2] - The company is enhancing its laboratory capabilities and business team configurations in key overseas regions, including Europe and Asia-Pacific [2] Group 2: Business Development and Market Engagement - The company has established a business development (BD) team of over ten members overseas and plans to strengthen the BD team in Europe [2] - There will be improved communication and collaboration between the overseas BD teams and domestic research teams, along with the establishment of a customer information intelligence system [2] - The company intends to actively participate in international industry conferences and increase the frequency of research team outreach to expand its overseas market presence [2]

Core Viewpoint - Zhaoyan New Drug (06127) has seen a significant stock price increase of over 9%, currently trading at 24.62 HKD, with a transaction volume of 391 million HKD, indicating positive market sentiment towards the company [1] Group 1: Company Performance and Outlook - Huatai Securities reports that Zhaoyan New Drug experienced high growth from 2018 to 2022, but is facing order volume and price pressures from 2023 to 2025. However, starting in 2026, the company is expected to enter a new growth phase driven by domestic recovery and overseas outsourcing [1] - The report highlights that the price of experimental monkeys, a key indicator of supply and demand in the safety evaluation industry, is currently stable at 80,000 to 100,000 RMB per monkey, with a potential upward trend as supply-demand gaps widen [1] Group 2: Market Concerns and Long-term Perspectives - Contrary to market concerns regarding the impact of FDA new policies and overseas business growth potential, Huatai Securities believes that the new policies are primarily focused on monoclonal antibodies and have not yet been adopted domestically. Animal testing will remain the dominant method in global drug safety evaluation for the next 3-5 years [1] - The long-term application of new methodologies such as AI and organoids is still uncertain, requiring careful consideration of transitional results and technological maturity. The company is expected to enhance its overall capabilities through proactive engagement with new methodologies [1]